glp-1 kelly clarkson Chief Medical Officer Reacts to Clarkson's Weight Loss Kelly Clarkson's Stunning Weight Loss:

Diabetologia 47 , 806815 (2004)

After that, clinical studies and post-release surveillance observations showed that individuals prescribed the drug were also losing weight

Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)

Ongoing medical monitoring allows doctors to assess appetite response, side effect patterns, and overall progress